Akkermansia muciniphila

A. muciniphila

BioticsMicrobiome & barrier

Aging selectively depletes the gut microbiome: certain protective species disappear well before others. Akkermansia muciniphila is one of them — a bacterium whose abundance declines with age and which consistently ranks among the most enriched microbiota signatures in centenarians. It acts via the Amuc_1100 protein, which reinforces intestinal mucosal tight junctions. This mechanism contributes to limiting the chronic low-grade systemic inflammation associated with aging. Its tyndallized form retains this biological activity without requiring a cold chain.

Last updated: March 25, 2026

Mechanism of Action

Akkermansia muciniphila's mechanism of action operates through a unique protein: Amuc_1100, located on its outer membrane. This surface protein is thermostable (denaturation temperature of approximately 70°C), which explains why the tyndallized form retains biological activity after cellular inactivation.

Amuc_1100 is a ligand for the TLR2 receptor (toll-like receptor 2), present on the surface of intestinal epithelial cells. When Amuc_1100 binds TLR2, it triggers a signaling cascade that stabilizes tight junction proteins: claudin-3, ZO-1, occludin. These junctions are the molecular seals between two adjacent epithelial cells. Their integrity determines the selective permeability of the mucosa.

An intact mucosa retains lipopolysaccharides (LPS) — bacterial wall fragments released during normal microbiota turnover — within the intestinal lumen. With age, these junctions loosen. LPS then pass into the bloodstream and chronically activate circulating immune cells, sustaining low-grade systemic inflammation — a phenomenon some researchers call "metabolic endotoxemia."

Akkermansia also stimulates colonic mucus production by goblet cells. Thicker mucus provides an additional physical barrier between the microbiota and the epithelium.

Key Benefits

Strong
A randomized controlled trial (Depommier et al., Nature Medicine 2019, n=32) showed that 12 weeks of supplementation with pasteurized Akkermansia improved insulin sensitivity by +28.6% and reduced fasting insulinemia by 34% versus placebo — two central markers of metabolic risk.
Strong
Akkermansia's Amuc_1100 protein activates TLR2 on intestinal epithelial cells and strengthens tight junctions, reducing the passage of bacterial lipopolysaccharides (LPS) into circulation — a mechanism documented in multiple preclinical models and partially confirmed clinically.
Moderate
Akkermansia muciniphila is among the microbiota signatures most consistently enriched in individuals with exceptional longevity in a meta-analysis covering 8 centenarian cohorts (Chen S et al., Gut Microbes 2024), without formal causality being established.
Moderate
A 12-week randomized double-blind clinical trial in adults over 60 (Kang CH et al., Nutrients 2024, PMID 39683431) showed that supplementation with pasteurized Akkermansia HB05P improved muscle strength and functional performance.
Moderate
Comparative data published in 2021 (Ashrafian F et al., Scientific Reports) indicate that the pasteurized form of Akkermansia produces metabolic effects comparable to or greater than the live form, validating the postbiotic approach for certain parameters.

Dosage & Forms

The dose used in the Singular formula is 100 mg per day, corresponding to 10 billion tyndallized cells (concentration of 100 billion cells per gram). This dosage matches that used in the reference trial by Depommier et al. (Nature Medicine, 2019), which documented the most significant metabolic effects at 10 billion cells per day.

The maximum dose authorized in the European Union under Novel Food status is 34 billion cells per day — more than three times the dose used in the formula. The regulatory safety margin is therefore wide.

The tyndallized form presents a dosimetric advantage over the live form. Its biological activity depends on the quantity of available Amuc_1100 protein, not on maintaining cell viability. A tyndallized batch can be dosed with a precision unachievable for live bacteria formulas, due to viability losses between manufacturing and consumption. Comparative studies showed the heat-inactivated form produced metabolic effects equivalent to the live form across several key parameters (Ashrafian F et al., Scientific Reports, 2021).

In the Singular Formula

Inclusion rationale

Akkermansia muciniphila is an anaerobic bacterium that colonises the colonic mucus layer. Its abundance in the human microbiome declines progressively with age — and analyses spanning multiple independent centenarian cohorts consistently identify Akkermansia among the most enriched microbiota signatures in individuals with exceptional longevity. The central mechanism involves the Amuc_1100 protein on its outer membrane, which interacts with intestinal epithelial cell receptors and reinforces the tight junctions controlling mucosal permeability. A less permeable mucosa reduces the passage of bacterial fragments into the general circulation, limiting the chronic low-grade systemic inflammation associated with aging. A randomised controlled trial published in Nature Medicine (2019), conducted in 32 overweight adults over 12 weeks, documented a +28.6% improvement in insulin sensitivity, a 34% reduction in insulinemia and an 8.7% decrease in total cholesterol versus placebo. The tyndallized form was selected because Amuc_1100 is thermostable and retains its activity after cellular inactivation, eliminating the viability constraints of the live form. The synergy with Bifidobacterium longum, Bacillus subtilis, GOS, zinc and vitamin D3 in the formula aims to support the entire mucosal ecosystem: GOS nourish the commensal flora, zinc consolidates tight junctions and vitamin D3 supports the immune component of the mucosa.

Selected form

Tyndallized Akkermansia muciniphila concentrated at 100 billion cells per gram. Tyndallization is a gentle heat-inactivation process: bacterial cells are heated to 65-70°C in a controlled cycle, inactivating them without denaturing their structural proteins. Unlike a live bacterium, a tyndallized cell requires neither cold chain nor gastro-resistant coating. The decisive advantage lies in the thermostability of the Amuc_1100 protein, located on Akkermansia's outer membrane: this structural protein survives tyndallization and retains its full capacity to interact with intestinal mucosal receptors. The tyndallized form thus delivers the functional active ingredient with a manufacturing stability that the live form cannot guarantee. Quality: vegan.

Formula dosage

0 to 100 mg.

Synergies in the formula

Tyndallized Akkermansia muciniphila integrates into a formulatory ecosystem designed around the intestinal mucosa as the primary interface between the microbiota and the rest of the organism. Bifidobacterium longum, a resident colonic probiotic, produces lactic acid and short-chain fatty acids. These metabolites lower luminal pH, creating an environment favorable to Akkermansia's persistence. The two species share the colonic mucosal niche without direct competition. Bifidobacterium longum acts on the luminal flora, Akkermansia on the epithelial interface via Amuc_1100. Bacillus subtilis, a transient sporebiotic, enriches the microbiota's metabolic repertoire with digestive enzymes and metabolites that resident species do not produce. Its temporary passage through the intestine precedes or accompanies Akkermansia's action without documented interference. Galacto-oligosaccharides (GOS) serve as a selective prebiotic substrate. They preferentially nourish bifidobacteria, support their establishment, and indirectly create favorable niche conditions for Akkermansia. Zinc contributes to the structural cohesion of tight junctions between epithelial cells, complementing through a direct mineral action the molecular signal that Akkermansia sends via TLR2. Vitamin D3 modulates the immune response of the intestinal mucosa via VDR receptors on epithelial and immune cells. This distinct signaling pathway reinforces local immune tolerance without interfering with Akkermansia's own mechanism.

Safety & Precautions

Tyndallized Akkermansia muciniphila has held European Union Novel Food authorization since February 2022, with a maximum daily dose set at 34 billion cells. The dose used in the Singular formula (10 billion cells, 100 mg) represents less than one-third of this regulatory limit.

In published clinical trials, no serious adverse events have been reported. Documented effects are limited to transient digestive discomfort (bloating, changes in transit) during the first weeks. These are comparable to those observed with other microbiota-targeting supplements.

The tyndallized form presents a distinct safety profile from the live form: since cells are inactivated, there is no risk of bacterial proliferation. Supplementation is nonetheless not recommended for individuals with significantly compromised immune defenses (severe immunosuppression), by application of the general precautionary principle.

Pregnant or breastfeeding women are invited to consult a healthcare professional before use, in the absence of specific clinical data for these populations. No notable pharmacokinetic interactions with common medications are documented to date.

Scientific Studies

Authors	Year	Type	Journal
Depommier C et al.	2019	Randomised Controlled Trial	Nature Medicine	View on PubMed
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study Randomized controlled trial (n=32, 12 weeks) showing pasteurized Akkermansia improves insulin sensitivity by +28.6%, reduces insulinemia by 34% and total cholesterol by 8.7% versus placebo. Landmark trial in the field.
Kang CH et al.	2024	Randomised Controlled Trial	Nutrients	View on PubMed
Pasteurized Akkermansia muciniphila HB05 (HB05P) Improves Muscle Strength and Function: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial 12-week randomized double-blind clinical trial in adults over 60 showing improved muscle strength and functional performance under pasteurized Akkermansia HB05P.
Chen S et al.	2024	Meta-analysis	Gut Microbes	View on PubMed
Consistent signatures in the human gut microbiome of longevous populations Meta-analysis across 8 cohorts of centenarians and individuals with exceptional longevity. Akkermansia is among the 3 most consistently enriched microbiota signatures, regardless of geographic origin.
Zeng SY et al.	2023	Systematic Review	Aging and Disease	View on PubMed
Potential Effects of Akkermansia muciniphila in Aging and Aging-Related Diseases: Current Evidence and Perspectives Review of Akkermansia's mechanisms of action in the context of aging. Includes a Mendelian randomization analysis suggesting a potential causal relationship between Akkermansia abundance and longevity.
Ashrafian F et al.	2021	Preclinical Study	Scientific Reports	View on PubMed
Comparative effects of alive and pasteurized Akkermansia muciniphila on normal diet-fed mice Comparative study showing the pasteurized form of Akkermansia produces metabolic effects at least equivalent to those of the live form, validating the postbiotic approach for certain lipid and metabolic parameters.

Frequently Asked Questions

What is the difference between tyndallized and live Akkermansia?#[ + ]

The live form contains active bacteria requiring refrigeration and partially dying during gastric passage. The tyndallized form contains heat-inactivated cells that require no cold chain. Biological activity relies on the Amuc_1100 protein, which is thermostable, survives inactivation and retains its capacity to interact with intestinal mucosal receptors. Comparative studies show equivalent metabolic effects between the two forms across several parameters.

How does Akkermansia affect intestinal permeability?#[ + ]

Akkermansia's Amuc_1100 protein binds to the TLR2 receptor on intestinal epithelial cells and triggers a signaling cascade that stabilizes tight junction proteins (claudin-3, ZO-1, occludin). These junctions are the molecular seals between adjacent epithelial cells. Their reinforcement reduces the passage of bacterial fragments — notably lipopolysaccharides (LPS) — into the bloodstream, thereby limiting chronic stimulation of the immune system.

What is the connection between Akkermansia and longevity?#[ + ]

Observational studies consistently show Akkermansia muciniphila is enriched in the microbiota of centenarians compared to ordinary older adults — a finding reproducible across 8 independent cohorts (Chen S et al., Gut Microbes 2024). A Mendelian randomization analysis suggests a potential causal relationship without providing formal proof. The most plausible mechanistic hypothesis is that Akkermansia's maintenance of intestinal barrier integrity contributes to reducing chronic systemic inflammation, a factor associated with several age-related conditions.

How long does it take to notice effects?#[ + ]

In the reference trial by Depommier et al. (2019), effects on insulin sensitivity and lipid parameters were measured after 12 weeks of daily supplementation. Digestive comfort parameters may evolve earlier, typically within the first 4 to 8 weeks. As with all ingredients targeting the microbiota, consistency of daily intake is the determining factor: effects build progressively and persist only with continued supplementation.

Can tyndallized Akkermansia be taken alongside other probiotics?#[ + ]

Yes. The mechanisms of action of tyndallized Akkermansia (via the Amuc_1100 protein and TLR2 receptor) are distinct from those of conventional probiotics (Bifidobacterium, Lactobacillus) and sporebiotics (Bacillus subtilis). These ingredients act on complementary ecological niches and signaling pathways. The Singular formula precisely combines tyndallized Akkermansia, Bifidobacterium longum and Bacillus subtilis to cover multiple levels of action on the intestinal ecosystem.

Discover all our bioactives